FDA Clears Emerging High-Resolution PET Scanner
Featuring advanced detector technology, the Pharos PET scanner reportedly enhances detection of subtle anomalies across brain, breast and extremity imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Pharos positron emission tomography (PET) scanner, which offers high-resolution imaging and streamlined workflow for a variety of nuclear imaging applications.
The high-resolution capability of the Pharos PET scanner enables early detection of subtle anomalies, according to Brightonix Imaging, the manufacturer of the device.
The newly FDA-cleared Pharos PET scanner offers enhanced high-resolution capability and tailored configurations for brain, breast and extremity imaging. (Image courtesy of Brightonix Imaging.)
Other attributes of the Pharos PET scanner include a streamlined design, which allows for a compact footprint, an intuitive interface that facilitates workflow efficiency, and tailored configurations for brain, breast and extremity imaging.
“This technology will empower health-care providers with the tools to detect and treat neurodegenerative diseases earlier and with greater precision, ultimately improving patient outcomes,” noted Jae Sung Lee, Ph.D., the CEO and founder of Brightonix Imaging.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
